Posted On: 01/23/2016 3:28:03 PM
Post# of 30070
I used this example partnering in ophthalmology gene therapy. AGTC got $124M upfront but they already had clinical data.
For those wondering why the company hasn't cut some partnering deals, it wasn't until November (2 months ago) that they decided to explore it. Here's an example:
Amarantus announced on Dec. 10 they retained WallachBeth Capital to evaluate strategic options for MANF gene therapy program.
http://www.amarantus.com/news/press-releases/...-strategic
Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy
http://www.xconomy.com/boston/2015/07/02/biog...e-therapy/
Pipeline:
http://www.agtc.com/index.php/products
For those wondering why the company hasn't cut some partnering deals, it wasn't until November (2 months ago) that they decided to explore it. Here's an example:
Amarantus announced on Dec. 10 they retained WallachBeth Capital to evaluate strategic options for MANF gene therapy program.
http://www.amarantus.com/news/press-releases/...-strategic
Biogen Offers Up To $1 Billion for AGTC’s Ophthalmology Gene Therapy
http://www.xconomy.com/boston/2015/07/02/biog...e-therapy/
Pipeline:
http://www.agtc.com/index.php/products
(0)
(0)
